Archive for the ‘landscape’ tag
Sanofi Pasteur
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Rituxan
Click on thumbnail to view the full-size ad on AdPharm
When planning a treatment course for DLBCL
Take the essential path toward improved survival
Rituxan + CHOP is proven to prolong survival in DLBCL
Brand name: Rituxan
Generic name/category: Rituximab, Monoclonal antibodies, Orphan drugs, Antineoplastic drugs
Company: Genentech BioOncology and Biogen idec
Country/Market: USA, North America
Indication(s)/use: diffuse large B cell lymphoma (DLBCL)
Target: Healthcare Professionals (HCP)
Tagline: Take the essential path toward improved survival
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 6, 2009
To see all of this brand’s ads on AdPharm, click here
Revatio HCP Print ad
New indication
A new reason to treat with Revatio…
Revatio delays clinical worsening in patients with PAH (WHO Group I)
Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was developed and is being marketed by the pharmaceutical company Pfizer. It acts by inhibiting cGMP specific phosphodiesterase type 5, an enzyme that regulates blood flow in the penis. Since becoming available in 1998, sildenafil has been the prime treatment for erectile dysfunction; its primary competitors on the market are tadalafil (Cialis) and vardenafil (Levitra).
As well as erectile dysfunction, sildenafil citrate is also effective in the rare disease pulmonary arterial hypertension (PAH). It relaxes the arterial wall, leading to decreased pulmonary arterial resistance and pressure. This in turn reduces the workload of the right ventricle of the heart and improves symptoms of right-sided heart failure. Because PDE-5 is primarily distributed within the arterial wall smooth muscle of the lungs and penis, sildenafil acts selectively in both these areas without inducing vasodilation in other areas of the body. Pfizer submitted an additional registration for sildenafil to the FDA, and sildenafil was approved for this indication in June 2005. The preparation is named Revatio, to avoid confusion with Viagra, and the 20 milligram tablets are white and round. Sildenafil joins bosentan and prostacyclin-based therapies for this condition.
Brand name: Revatio
Generic name/category: Sildenafil, PDE5 inhibitors, Citrates
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: Pulmonary Arterial Hypertension (PAH)
Target: Healthcare Professionals (HCP)
Tagline: Start with confidence
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: Chest – August 2009
Sustiva – skyline
Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with lamivudine/zidovudine (Combivir) or tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults and adolescents.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
The usual adult dose is 600 mg once a day. It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.
Efavirenz was combined with the popular HIV medication Truvada, which consists of tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications approved by the U.S. Food and Drug Administration (FDA) in July 2006 under the brand name Atripla, provides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.
Brand name: Sustiva
Generic name/category: Efavirenz, Non-nucleoside reverse transcriptase inhibitors, Alkynes, World Health Organization essential medicines
Company: Bristol-Myers Squibb BMS
Country/Market: USA, North America
Indication(s)/use: HIV combination therapy
Target: Healthcare Professionals (HCP)
Tagline: Thousands of stories
Medium: Web banner
Size/duration: 728X90
Publication/Aired: www.infectiousdiseasenews.com – September 2009
0 views
Sep 03, 2009
Visit AdPharm.net for more pharmaceutical ads
Eloxatin – Sailboat
Deux contextes… Pensez à Eloxatin
Métastatique/Adjuvant
Schéma FOLFOX4 a démontré
Dans le traitement adjuvant du cancer du côlon de stade III (vs le schéma 5-FU/LV):
Amélioration de la survie sans maladie.
Amélioration quantitative de la survie globale.
Dans le traitement du cancer colorectal métastatique chez les patients n’ayant reçu aucun traitement préalable (vs le schéma IFL):
Amélioration de l’intervalle médian dans progression de la maladie.
Prolongation de la survie globale médiane.
Two contexts … Think of Eloxatin
metastatic/adjuvant
Figure FOLFOX4 demonstrated
In the adjuvant treatment of colon cancer stage III (vs 5-FU/LV):
Improved disease-free survival.
Quantitative improvement in overall survival.
In the treatment of metastatic colorectal cancer patients who received no prior treatment (vs. IFL diagram):
Improved median interval in disease progression.
Extension of the median overall survival.
Oxaliplatin is a platinum-based cancer chemotherapy drug. These drugs are usually classified as alkylating agents, although they are not capable of actually adding alkyl groups to DNA and simply work by a similar mechanism.
Oxaliplatin is typically administered with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin or by Medac GmbH under the trademark Oxaliplatin Medac. There are generic equivalents on the market now
Brand name: Eloxatin
Generic name/category: Oxaliplatin, Oncology, chemotherapy
Company: Sanofi Aventis
Country/Market: Canada, North America
Indication(s)/use: colorectal cancer
Target: Healthcare Professionals (HCP)
Tagline: Un choix éprouvé – A reliable choice
Medium: Print ad
Size/duration: single-page
Publication/Aired: Le Patient – July 2009
To see all of this brand’s ads on AdPharm, click here
Visit AdPharm.net for more pharmaceutical ads
Humalog Mix 25 – Mountains
Help your patients see convenient insulin therapy more clearly.
Give your patients another option towards glycemic control.
Humalog Mix25 twice-a-day – basal and mealtime insulin analogues conveniently combined in a single pen – may be just what they have been looking for.
Open the dialogue to Humalog.
Insulin lispro (marketed by Eli Lilly and Company as “Humalog”) is a fast acting insulin analogue; it was the first insulin analogue.
It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections.
It has been shown by Shimoda et al. that, when comparing three insulin delivery methods, i.v. (intravenous) regular insulin, s.c. (subcutaneous) insulin Lispro, and s.c. regular insulin, that s.c. insulin Lispro performs almost as well as i.v. regular insulin in handling meal disturbances. S.c. regular insulin performed worse than s.c. insulin lispro, resulting in postprandial glucose peaks, in addition to postprandial hypoglycemia.
Brand name: Humalog Mix 25
Generic name/category: 25% Insulin lispro injection rDNA origin, 75% insulin lispro protamine suspension
Company: Lilly
Country/Market: Canada, North America
Indication(s)/use: diabetes
Target: Healthcare Professionals (HCP)
Tagline: Open the dialogue to Humalog.
Medium: Print ad
Size/duration: single-page
Publication/Aired: CMAJ – August 4, 2009
To see all of this brand's ads on AdPharm, click here
5 views
Aug 11, 2009
Visit AdPharm.net for more pharmaceutical ads
Sanofi Pasteur
Because you’re in the business of moving mountains… we’re in the business of supporting you
Reimbursement issues, cash flow, vaccine schedules, and many other daily distractions–the practice of medicine clearly has its challenges. As specialists in vaccines, at sanofi pasteur, our commitment to you and your practice means we’re ready to help you overcome those challenges every day. Online vaccine ordering, practice and patient information, and inventory monitoring solutions are a few of the tools we offer to help you stay focused on disease prevention.
Greater together
Generic name/category: corporate ad, vaccines
Company: Sanofi Pasteur
Country/Market: USA, North America
Indication(s)/use: viral infections
Target: Healthcare Professionals (HCP)
Tagline: Greater together
Medium: Print ad
Size/duration double-page spread
Publication/Aired: Contemporary Pediatrics July 2009
To see all of this brand’s ads on AdPharm, click here
